RxDoctor Payments Data

Erin McCoy, MD

Gastroenterology · Nampa, IDNPI 1700010873

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $803 of the $893 with a category attached, or 89.9%. 11 manufacturers reported payments, led by AbbVie at 49.1% of the total. Reporting peaked in 2019 at $282 and has fallen 71.1% since, to $81 in 2025. That places this record below the midpoint for gastroenterology clinicians in ID, where the typical reported total is $1,538.

$893in general payments, 2019–2025

Across 45 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$438
  • Johnson & Johnson$137
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$72
  • Aimmune Therapeutics, Inc.$64
  • Pfizer$45
  • Merck$41
  • plus $95 from 5 others

What the payments were for

  • Food & beverage$80390%
  • Education$9010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$893 in reported general payments places this provider in the 40th percentile of 70 gastroenterology providers in Idaho.

See all gastroenterology providers in Idaho

Medicare billing

Part B allowed, 2024
$73,116
Medicare patients
353
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi On-BodyRisankizumab-Rzaa12$253,089
Mesalamine21$20,476
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates226$14,932
Budesonide DrBudesonide14$4,141
Omeprazole157$2,123
Vancomycin Hcl13$2,115
Lubiprostone12$1,400
Ondansetron OdtOndansetron314$1,123
Dicyclomine Hcl37$1,035
Pantoprazole Sodium63$845
Esomeprazole Magnesium24$814
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl30$559
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl36$541
Lactated RingersRinger's Solution,lactated29$425
Famotidine20$350

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →